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Objectives: Sunitinib is the standard care for first-line treatment of metastatic renal
cell carcinoma. The aim of this study was to determine whether a sunitinib regimen of
50 mg/day 2-weeks on/1-week off could maintain the same dose-intensity as the stand-
ard 4-weeks on/2-weeks off schedule, and provide the same efficacy in terms of objec-
tive response, progression-free survival and overall survival, while reducing drug-related
toxicity.
Methods: A total of 31 patients withmetastatic renal cell carcinoma received sunitinib
orally at the dose of 50 mg/day in a 2-weeks on/1-week off regimen until disease pro-
gression or intolerable toxicities occurred.
Results: All enrolled patients were assessable in terms of toxicity and response. They
received treatment for a median of 16 months (range 2.0–36.0+ months). A total of 13
patients (42%) obtained an objective response; disease stabilization was achieved in 10
patients (32%), whereas eight patients (26%) experienced disease progression. The most
important toxicities were anemia, gastrointestinal effects, fatigue and hypertension, but
they were all controlled.
Conclusions: Sunitinib 50 mg given orally in a 2-weeks on/1-week off regimen can
provide a high response rate and avoid drug-related toxicities, achieving the same dose
intensity as the standard schedule, and probably longer disease control.
Key words: metastatic renal cell carcinoma, renal cancer medical treatment,
sunitinib, treatment toxicity, tyrosine kinase inhibitors.
Introduction
In the past 10 years, the medical treatment of solid tumors has produced significant results,
but there is a paucity of results to date regarding mRCC. There is therefore an urgent need
to identify new active agents to combat this carcinoma.1 Until a few years ago, the 5-year
mRCC survival rate was estimated at less than 10%,2 because mRCC has proved to be
highly resistant to conventional chemotherapy, which involves the use of cytotoxic drugs.
Thus, only a small group of patients, approximately 20%, has benefited from the use of
cytokines, such as INF-a or IL-2, obtaining a mean survival rate of approximately
10–12 months.3–7 At the same time, recent experimental and clinical studies have shown that
RCC is characterized by varying histology. In this way, it has been possible to show how the
loss of specific protein functions, typical of von Hippel-Lindau syndrome, but also found in
sporadic clear cell RCC, can determine the production of factors linked to hypoxia events8–10
and consequently induce an overexpression of VEGF and PDGF. These factors have been
found to promote angiogenesis that directly contributes to the hypervascularization found in
RCC. From these preliminary studies, it can be readily surmised that inhibition of VEGF
and PDGF receptors should at least partly control tumor angiogenesis.11,12 In this context,
sunitinib malate (Pfizer, La Jolla, CA, USA) has been found to be the most promising of the
targeted molecular drugs proposed for the treatment of mRCC. It is a new orally active
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multi-target tyrosine kinase inhibitor, capable of specifically
inhibiting theVEGF (types 1–3) and PDGF (a and b) recep-
tors, and also effectively blocking other tyrosine kinases.13,14
The present study was undertaken to investigate whether
sunitinib, orally administered at the dose of 50 mg/day in
3-week cycles, 2-weeks on/1-week off schedule (2/1-week),
can reduce the incidence of the most significant drug-related
side effects (WHO criteria) while maintaining the standard
planned drug dose intensity.15 Another goal of the study was
to verify the effectiveness of the “2/1-week regimen” in
terms of OR (OR = CR + PR) according to the Response
Evaluation Criteria in Solid Tumors,16 PFS and OS com-
pared with the standard regimen.
Methods
Patients
Patients with metastatic RCC were considered eligible for
the study.
Eligibility criteria
• Histologically documented metastatic clear cell kidney
tumor
• Patient’s written informed consent
• Age 18 years or older
• Previous nephrectomy for clear cell renal carcinoma
• Presence of measurable metastatic disease
• Performance status of 0 or 1 according to Eastern Coop-
erative Oncology Group
• Adequate renal and hepatic function assessed with
normal laboratory tests
• Adequate cardiac function
• Must have suspended any previous cytokine treatment
for at least 4 weeks.
The study was carried out in accordance with the declaration
of Helsinki and Good Clinical practice criteria. All patients
gave their informed written consent after being thoroughly
informed of the study design, benefits and risks according to
the guidelines of Local Ethics Committee.
Exclusion criteria
• Presence of cerebral metastasis
• Ischemic heart disease (with documented evidence for
the 12 months preceding the start of the treatment).
Study design and treatment regimen
In the present study, we evaluated a total of 31 patients who
received sunitinib 50 mg orally in a 2/1-week schedule.
Before the start of the study, 10 patients had received
sunitinib 50 mg orally in a 4/2-week regimen that was modi-
fied when toxicity of grade 2 (WHO) was documented.
Then the treatment schedule was modified with the same
dose of 50 mg/day of sunitinib, but in a 2/1-week schedule
instead of reducing the sunitinib dose to 37.5 mg or 25 mg.
At the same time, 21 other patients were enrolled who
received sunitinib 50 mg/day in the 2/1-week schedule from
the beginning of the study. Alternatively, the dose of
sunitinib 50 mg/day was reduced to 37.5 or 25 mg/day,
depending on the severity and duration of the toxic effect
observed. The treatment was suspended in the event of
disease progression, toxicity grade 3 or if the patient
requested treatment suspension.
Baseline evaluation
At the start of the study and every 3 months thereafter, the
patients underwent a full physical examination, diagnostic
monitoring of the tumor (brain, chest, abdomen and pelvis
scan with computed tomography or magnetic resonance
imaging scan, whole body bone scintigraphy and PET when
considered necessary, ECOG performance status evaluation;
laboratory tests (blood chemistry and coagulation tests,
urine tests); electrocardiogram and measurement of the left
ventricle ejection fraction by means of echocardiogram.
Thyroid function was also evaluated periodically by moni-
toring the TSH, T3 and T4 values.
Statistical methods
The study was planned as a non-randomized phase II study.
The size of the sample was calculated in the expectation of
reaching an objective response level varying between 20 and
40%. Thus, according to the Simon two-stage method,17 if a
minimum of objective responses >20% was achieved in the
first 15 patients enrolled, enrolment of further patients
would have been reasonable. PFS and OS were analyzed
according to the Kaplan–Meier method,18 and plotted with
confidence intervals at 95%.19 The patients who were alive
were assessed on the last date of the periodic check-up.
Results
Patients’ characteristics
From January 2008 to May 2010, 31 patients with mRCC
were enrolled in the study. The final analysis of the data
relating to the study was carried out in May 2011. At the
time of joining the study, all 31 patients (100%) presented
with an ECOG performance status 2 and metastatic
disease, with 13 patients (42%) presenting with metastatic
disease in three or more sites and the lung was the most
frequently affected organ. All patients were also classified
according to risk classes according to Motzer et al.20 The
clinical characteristics of patients are reported in Table 1.
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Sunitinib was given to 21 patients (68%) as first-line
treatment, whereas 10 patients (32%) had previously
received cytokine treatment. Patients received sunitinib for a
median of 16 months (range 2.0–36.0 months). Sunitinib
was given orally at a dose of 50 mg/day in 2/1-week
regimen. During the study, the daily sunitinib dose had to be
reduced to 37.5 mg/day for grade 2 (WHO) toxicity in
four our of 31 patients (13%).
Efficacy
All 31 patients enrolled in the study were assessable for OR
(OR = CR+PR), PFS and OS, which are summarized in
Table 2. Three patients (10%) obtained a CR for the meta-
static lesions in the lung and lymph gland system; 10
patients (32%) obtained PR with an OR of 42%. Disease
stabilization was recorded in 10 patients (32%), whereas the
remaining eight patients (26%) presented progression. All
the responses were related to target lesions. Skeletal lesions
were not included in the response evaluation, as they were
treated with zoledronic acid (4 mg/month intravenously)
and where necessary, with targeted radiation therapy for
analgesic purposes. At the time of data analysis, six out of
31 patients (19%; of the eight [26%] recorded with disease
progression) died, whereas the other two patients (6%) who
had progression, after suspension of the sunitinib treatment,
moved to second-line treatment with temsirolimus (Torisel).
A total of 24 patients (77%) were still alive after 36 months
of treatment. Figures 1 and 2 show the PFS trend, the
median value of which is 16.4 months (range 4–36 months,
Table 1 Characteristics of the patients at the start of the
study
Characteristics Current study Motzer’ study
n (%) n (%)
Total population involved
in the study
31 (100) 106 (100)
Median age (range) 68 years
(50–85
years)
56 years
(32–79
years)
Sex
Males 19 (61) 67 (63)
Females 12 (39) 39 (37)
ECOG: performance status
0 11 (35) 58 (55)
1 20 (64) 48 (45)
No. metastatic sites
1 10 (32) 13 (12)
2 8 (26) 38 (36)
3 13 (42) 55 (52)
Metastatic sites
Lung 18 (58) 86 (81)
Liver 5 (16) 29 (27)
Bone 8 (26) 27 (26)
Lymph nodes 11 (35) 62 (59)
Soft tissue 9 (29) –
Contralateral kidney 2 (6) –
MSKCC: risk factor†
0 16 (52) 61 (58)
1 15 (48) 45 (42)
†Risk factors associated with shorter survival according to
MSKCC risk classification.
Table 2 Extent of the objective response to treatment with
sunitinib
Extent of the response Patients examined
n %
CR 3 10
PR 10 32
CR + PR (OR) 13 42
Disease stability 3 months 10 32
Progression of the disease, stability
<3 months or non-assessable
8 26
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Fig. 1 Kaplan–Meier curve referring to the calculation of PFS
in patients with mRCC treated with sunitinib.
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Fig. 2 Kaplan–Meier curve referring to the calculation of OS
in patients with mRCC treated with sunitinib.
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95% CI 10.8–22.0), and OS, the median duration of which
was 18.1 months (range 6–36 months, 95% CI 15.0–22.2).
We believe that the median values of PFS and OS are so
close together because the period of follow up was too short.
Safety
Overall, 31 patients were treated with sunitinib for
2 months and were included in the safety analysis. The
most important sunitinib-related toxic effect was anemia
(WHO grade 2), which was recorded in seven out of 31
patients (23%), and was easily controlled by administering
erythropoietin, following an intravenous iron supplement,
when necessary. More frequent was stomatitis/diarrhea in
five patients (17%). Another significant side-effect was arte-
rial hypertension, which was recorded in eight patients
(26%), but always pharmacologically controllable. Last, a
significant increase in TSH values was recorded from
cycle II of the treatment in five patients (16%), although it
was not accompanied by clinical manifestations of hypothy-
roidism. After 12 months of sunitinib treatment, we
observed cardiac symptoms in one patient, who died of
acute heart failure. Table 3 summarizes all the adverse
events recorded and their grade during the treatment.
Regarding all 31 patients entered in the study: 10 out of 31
patients were treated with the 4/2-weeks regimen and to 21
out of 31 patients were treated with the 2/1-week regimen.
We observed a better control of blood pressure (reduced use
of antihypertensive drugs) and a reduction of the degree of
anaemia – fatigue. In Table 4, the results for response and
degrees of toxicity of the 21 patients who from the begin-
ning of the study received sunitinib in a 2/1-week regimen
are compared with the results of the study by Motzer et al.21
Discussion
Metastatic RCC has been considered one of the malignan-
cies that is most difficult to treat with chemotherapy and/or
Table 3 Most common adverse events linked to treatment with sunitinib, identified by grade of severity
Adverse events Patients (n = 10) Patients (n = 21)
4/2-Week regimen 2/1-Week regimen
Grade 2 Grade 3 Grade 4 Total % Grade 2 Grade 3 Grade 4 Total %
Anorexia 2 – – 20 1 – – 5
Emesis 1 – – 10 – – – –
Fatigue 1 2 – 30 3 – – 14
Nausea 1 – – 10 1 – – 5
Mucositis – diarrhea 1 1 – 20 3 – – 14
Bleeding 2 – – 20 1 – – 5
Rash – 1 – 10 2 – – 10
Hand-foot syndrome 1 – – 10 1 – – 5
Hypertension 3 1 – 40 4 – – 20
Cardiotoxicity – – 1 10 – – – –
Blood chemistry changes
Neutropenia – 1 – 10 2 – – 10
Anemia 2 1 – 30 4 – – 20
Platelet disorder 1 – – 10 – – – –
↑TSH 3 – – 30 2 – – 10
Table 4 Comparison between the most significant data in terms of response and adverse events in Motzer’s study and the
current study referring to the 21 patients treated with sunitinib 2/1-week regimen
Study Response Most significant toxicities (WHO grade 2) Dose
reduction
cases
(%)
OR – PFS – OS Anaemia – Fatigue – Mucositis – Hypertension
(%) (months) (%)
Motzer’study (regimen 4/2-week) 44 8 26 27 30 13 27 26
Present study† (regimen 2/1-week) 43 13 20 19 13 12 19 9
†The patients characteristics were comparable with those reported in Motzer’s study.
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radiation therapy because of the hyperexpression of the
resistance mechanisms to these therapeutic approaches. The
histopathological variety most commonly found in RCC is
the clear cell form, which presents with highly frequent
mutations that are capable of determining neo-angiogenesis
and hypervascularization.8,9 In the past 10 years it has been
possible to develop a group of molecules that can control
angiogenesis, although not completely, by blocking the
tyrosine-kinase receptors, in particular theVEGF and PDGF
receptors. In recent times, a number of new drugs and thera-
peutic regimens have been proposed for the treatment of
mRCC. The data in the literature seem to give a prominent
role to sunitinib malate, a specific inhibitor of the tyrosine-
kinase receptors, VEGFR and PDGFR, as first-line treat-
ment of mRCC. At the same time, as one of the most
significant aspects of targeted molecular therapies is the
need to continue the treatment until progression of the
disease, special attention must be addressed to monitoring
any drug-related side-effects, while at the same time under-
standing the mechanisms that give rise to them and their
control in order to maintain adequate dose intensity of the
drug given. To date, in mRCC, the pattern of standard treat-
ment involves the administration of sunitinib orally, 50 mg/
day in 4/2-week cycles.21 Furthermore, among related side-
effects, the rapidity of onset of arterial hypertension is
probably determined by the reduction of the microvascular
bed with a consequent increase in peripheral resistance.Yet,
it is a common observation that sunitinib-related hyperten-
sion tends to spontaneously revert to the normal range
during sunitinib suspension. Furthermore, preclinical
experiments have shown tumor growth during the sunitinib
off-dosing period.22,23 In light of these observations, more
recently a new phase I study17 was undertaken to investigate
sunitinib administration in 3-week courses (2/1-week) to
increase the total exposure time by reducing the length of
the off-drug period. Other later clinical trials investigated
the possibility of guaranteeing equivalent sunitinib activity
and efficacy, as well as manageable tolerability in long-term
treatment of mRCC, giving sunitinib at the dose of 37.5 mg
in a once-daily continuous dosing regimen.24,25 However, the
efficacy and safety profiles in these studies were not superior
to those observed when sunitinib was given on 4/2-week
schedule. Therefore, we believe that the continuous once-
daily dosing of sunitinib might be an alternative only in
selected circumstances. Regarding the results reported in the
present trial, the primary purpose was to verify if the
sunitinib regimen 50 mg/day in a 2/1-week cycle, maintain-
ing the same dose intensity as the standard 4/2-week sched-
ule, can reduce drug-related toxicity while maintaining the
same efficacy. Table 4 shows the results of this compared
with those of the study byMotzer,21 which can be considered
the reference study for the treatment of mRCC. In terms of
response, the results appear to be closely comparable,
although we observed fewer objective responses, and higher
numbers of patients with disease stabilization, progression
free survival and overall survival. However, the most rel-
evant result was the better control of sunitinib-related tox-
icity, which allowed the continuation of treatment without
delays or dose reductions. The present phase II trial con-
firmed the efficacy of sunitinib treatment in mRCC and
showed that the 2/1-week schedule is tolerable, although
patients might require minor dose adjustments and/or
modifications. In addition, the absence of significant drug
accumulation between courses17 suggests that prolonged
sunitinib exposure is feasible over a long period of treat-
ment, allowing us to maintain an adequate sunitinib dose
intensity administration. However, we believe these results
must be verified in a large series of patients for a longer
period.
Acknowledgments
We thank all of the patients and their families for their
participation in this study. Editorial assistance was provided
by Grazia Cini Ph.D. and writing support by Mary Forrest
Ph.D. The study was partially funded by “Associazione
Toscana Ricerche e Cure Oncologiche” Florence, Italy.
Conflict of interest
None declared.
References
1 Curti B. Renal cell carcinoma. JAMA 2004; 292: 97–100.
2 Motzer RJ, Bander NH, Nanus DM. Renal cell carcinoma.
N. Engl. J. Med. 1996; 335: 865–75.
3 Motzer RJ, Russo P. Systemic therapy for renal cell
carcinoma. J. Urol. 2000; 163: 408–17.
4 Wirth MP. Immunotherapy for metastatic renal cell
carcinoma. Urol. Clin. North Am. 1993; 20: 283–95.
5 Law TM, Motzer RJ, Mazumdar M et al. Phase III
randomized trial of interleukin-2 with or without
linphokine-activated killer sense in the treatment of patients
with advanced renal cell carcinoma. Cancer 1996; 76:
824–32.
6 Vogelzang NJ, Lipton A, Figlin RA et al. Subcutaneous
interleukin-2 plus interferon-a- in metastatic renal cancer.
J. Clin. Oncol. 1993; 11: 1809–16.
7 Escudier B, Chevreau C, Lasset C et al. Citokines in
metastatic renal cell carcinoma. J. Clin. Oncol. 1999; 17:
2039–43.
8 Kondo K, Kaelin WG Jr. The von Hippel-Lindau tumor
suppressor gene. Exp. Cell Press 2001; 264: 117–25.
9 Kondo K, Yao M, Yoshida M et al. Comprehensive
mutational analysis of the VHL gene in sporadic renal cell
carcinoma. Genes Chromosomes Cancer 2002; 34: 58–68.
10 Kim W, Kaelin WG Jr. The von Hippel-Lindau tumor
suppression protein: new insights into oxygen sensing and
cancer. Curr. Opin. Genet. Dev. 2003; 13: 55–60.
Sunitinib in metastatic renal cell carcinoma
© 2012 The Japanese Urological Association 5
11 Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington
JM. Sunitinib inhibits KIN and platelet-derived growth
factor receptor b in preclinical models of human small cell
lung cancer. Mol. Cancer Ther. 2003; 2: 471–8.
12 O’Farrel AM, Abrams TJ, Yuen HA et al. SU11248 is a
novel FLT3 tyrosine kinase inhibitor with potent activity in
vitro and in vivo. Blood 2003; 101: 3597–605.
13 O’Farrel AM, Foran JM, Fiedler W et al. An innovative
phase I clinical study demonstrates inhibition of FLT3
phosphorylation by SU11248 in acute myeloid leukemia
patients. Clin. Cancer Res. 2003; 9: 5465–76.
14 Mendel DB, Laird AD, Xin X et al. In vivo antitumor
activity of SU11248, a novel tyrosine kinase inhibitor
targeting vascular endothelial growth factor and
platelet-derived growth factor receptors. Clin. Cancer Res.
2003; 9: 327–37.
15 Britten CD, Kabbinavar F, Hecht JR et al. A phase I and
pharmacokinetic study of sunitinib administered daily for 2
weeks, followed by a 1 week off period. Cancer Chemoter
Pharmacol. 2008; 61: 515–24.
16 Therasse P, Arbuck SG, Eisenhauer EA et al. New
guidelines to evaluate the response to treatment in solid
tumors. J. Natl. Cancer Ins. 2000; 92: 205–16.
17 Simon R. Optimal two-stage designs for phase II clinical
trials. Control. Clin. Trials 1989; 10: 1–10.
18 Kaplan E, Meier P. Non-parametric estimation from
incomplete observation. J. Am. Stat. Assoc. 1958; 53:
457–81.
19 Lentner C. Extract confidence limits. Geigy scientific tables
1982;89–102.
20 Motzer RJ, Bacik J, Schwartz LH et al. Prognostic factors
for survival in previously treated patients with metastatic
renal cell carcinoma. J. Clin. Oncol. 2004; 22: 454–63.
21 Motzer RJ, Brian I, Ronald M et al. Sunitinib in patients
with metastatic renal cell carcinoma. JAMA 2006; 295:
2516–24.
22 Abrams TJ, Murray LJ, Pesenti E et al. Preclinical
evaluation of the tyrosine kinase inhibitor SU11248 as a
single agent and in combination with “standard of care”
therapeutic agents for the treatment of breast cancer. Mol.
Cancer Ther. 2003; 2: 1011–21.
23 Fielder W, Seve H, Dohner H et al. A phase I study of SU
11248 in the treatment of patients with refractory or
resistant acute myeloid leukemia or not amenable to
conventional therapy for the disease. Blood 2005; 105:
986–93.
24 Escudier B, Roigas J, Gillssen S et al. Phase II study of
sunitinib administered in a continuous once-daily dosing
regimen in patients with cytokine-refractory metastatic
renal cell carcinoma. J. Clin. Oncol. 2009; 27: 4068–75.
25 Barrios CH, Hernandez-Barajas D, Brown MP et al. Phase
II trial of continuous once-daily dosing of sunitinib as
first-line treatment in patients with metastatic renal cell
carcinoma. Cancer 2012; 118: 1252–9.
B NERI ET AL.
6 © 2012 The Japanese Urological Association
